The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over ...

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the ...

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – ...

Artificial intelligence has the potential to improve ophthalmology practices by streamlining documentation, enhancing ...

On World Sight Day, leading experts in ophthalmology look at artificial intelligence and how it could impact diagnosing and ...

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics ...

The phase 3 clinical trial is a randomized, double-blind, three-arm study comparing MELT-300, sublingual midazolam, and ...

MJH Life Sciences, parent company of Ophthalmology Times, has acquired The EnVision Summit. The meeting, held annually in ...

The effort represents a consortium of researchers from Penn Medicine, Penn Engineering, the University of Michigan Kellogg ...

EO2002 is a first-in-class, non-surgical cell therapy for corneal edema, utilizing Emmecell's Magnetic Cell Delivery platform. The phase 1 trial involves 21 patients in a randomized, double-masked, ...